** Materials for this course will release 04/29/2020 **

Oncology Pharmacy Specialty Review Course for Recertification + RECERT EXAM (Cert # L209089)

Teaser: This online course will help you earn BCOP recertification credit. With this course, get comprehensive, practical guidance, with a variety of complex cases, including references for further study.

Tag: Certifications; Oncology

ACPE Numbers: Various – see listing below
Pre-Sale Date: 04/15/2020
Content Release Date: 04/29/2020
Expiration Date: 04/13/2021
Activity Type: Application-based
CE Credits: 25.75 (BPS and ACPE)
Activity Fee: $475 (ASHP member); $675 (non-member)

Accreditation for Pharmacists
The American Society of Health-System Pharmacists and the American College of Clinical Pharmacy are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

These activities were recorded during a live educational event on March 5-7, 2020, at the ACCP/ASHP's 2020 Live Review & Recert Courses, Henderson, Nevada. Learners who claimed credit for the live activities should not claim credit for these home study activities.

Target Audience
These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in oncology pharmacy.

Activity Overview
This course is intended for BCOPs in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS) to provide an overview of recent standards and guidelines that specialists should be familiar with in practice. The course uses a case-based approach to discuss patient care issues. In this series, faculty will:

- Review pertinent clinical topics and practice skills
- List valuable resources for further self-study
This online course consists of 20 activities (see table below) and provides up to 25.75 hours of continuing pharmacy education credit and/or recertification credit.

**Recertification Credit**
Board certified pharmacists are eligible to receive up to 25.75 hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

This course is not intended for those preparing to take the BPS Oncology Pharmacy Specialty Examination for Certification. To prepare for the examination, please see courses here: [http://elearning.ashp.org/catalog/onc-review](http://elearning.ashp.org/catalog/onc-review)

These activities are part of the ASHP and ACCP professional development program for BCOP recertification approved by the BPS.

*Please note: Review Course for Recertification may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle.*

<table>
<thead>
<tr>
<th>Learning Activity</th>
<th>ACPE Number</th>
<th>Credit Hours</th>
<th>*Assessment Pass Point</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oncology Pharmacy Specialty Review and Recertification Course: Breast Cancer</td>
<td>0204-9999-20-922-H01-P</td>
<td>2.50</td>
<td></td>
</tr>
<tr>
<td>Oncology Pharmacy Specialty Review and Recertification Course: Gynecologic Malignancies</td>
<td>0204-9999-20-914-H01-P</td>
<td>1.00</td>
<td>TBD</td>
</tr>
<tr>
<td>Oncology Pharmacy Specialty Review and Recertification Course: Prostate Cancer</td>
<td>0204-9999-20-916-H01-P</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td>Oncology Pharmacy Specialty Review and Recertification Course: Pediatric Malignancies and Supportive Care</td>
<td>0204-9999-20-926-H01-P</td>
<td>1.25</td>
<td></td>
</tr>
<tr>
<td>Group 1 Assessment</td>
<td>5.75</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology Pharmacy Specialty Review and Recertification Course: Upper Gastrointestinal and Hepatocellular Carcinomas</td>
<td>0204-9999-20-924-H01-P</td>
<td>0.75</td>
<td></td>
</tr>
<tr>
<td>Oncology Pharmacy Specialty Review and Recertification Course: Bladder, Renal Cell, and Testicular Cancers</td>
<td>0204-9999-20-929-H01-P</td>
<td>1.00</td>
<td>TBD</td>
</tr>
<tr>
<td>Oncology Pharmacy Specialty Review and Recertification Course: Melanoma and Non-Melanoma Skin Cancers</td>
<td>0204-9999-20-915-H01-P</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td>Oncology Pharmacy Specialty Review and Recertification Course: Research Design, Statistics, and Evaluating Oncology Literature</td>
<td>0204-9999-20-912-H04-P</td>
<td>2.00</td>
<td></td>
</tr>
<tr>
<td>Group 2 Assessment</td>
<td>4.75</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
** Materials for this course will release 04/29/2020 **

<table>
<thead>
<tr>
<th>Course Title</th>
<th>Code</th>
<th>Credit Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oncology Pharmacy Specialty Review and Recertification Course:</td>
<td>0204-9999-20-928-H01-P</td>
<td>1.50</td>
</tr>
<tr>
<td>Adult Acute Leukemias and Myelodysplastic Syndromes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology Pharmacy Specialty Review and Recertification Course: Lymphomas</td>
<td>0204-9999-20-925-H01-P</td>
<td>1.25</td>
</tr>
<tr>
<td>Oncology Pharmacy Specialty Review and Recertification Course: Chronic</td>
<td>0204-9999-20-917-H01-P</td>
<td>1.50</td>
</tr>
<tr>
<td>Leukemias</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology Pharmacy Specialty Review and Recertification Course:</td>
<td>0204-9999-20-921-H01-P</td>
<td>1.25</td>
</tr>
<tr>
<td>Hematopoietic Stem Cell Transplantation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group 3 Assessment</td>
<td></td>
<td>5.50</td>
</tr>
<tr>
<td>Oncology Pharmacy Specialty Review and Recertification Course: Lung Cancer</td>
<td>0204-9999-20-923-H01-P</td>
<td>1.50</td>
</tr>
<tr>
<td>Oncology Pharmacy Specialty Review and Recertification Course:</td>
<td>0204-9999-20-927-H01-P</td>
<td>1.25</td>
</tr>
<tr>
<td>Lower Gastrointestinal and Pancreatic Cancers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology Pharmacy Specialty Review and Recertification Course:</td>
<td>0204-9999-20-930-H01-P</td>
<td>1.00</td>
</tr>
<tr>
<td>Head, Neck and Adult Central Nervous System (CNS) Malignancies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology Pharmacy Specialty Review and Recertification Course:</td>
<td>0204-9999-20-931-H01-P</td>
<td>1.00</td>
</tr>
<tr>
<td>Cancer-related Infectious Diseases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group 4 Assessment</td>
<td></td>
<td>4.75</td>
</tr>
<tr>
<td>Oncology Pharmacy Specialty Review and Recertification Course:</td>
<td>0204-9999-20-920-H04-P</td>
<td>2.00</td>
</tr>
<tr>
<td>Oncology Practice Management</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology Pharmacy Specialty Review and Recertification Course:</td>
<td>0204-9999-20-918-H01-P</td>
<td>1.50</td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology Pharmacy Specialty Review and Recertification Course:</td>
<td>0204-9999-20-919-H01-P</td>
<td>0.75</td>
</tr>
<tr>
<td>Adult Sarcoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology Pharmacy Specialty Review and Recertification Course:</td>
<td>0204-9999-20-913-H01-P</td>
<td>0.75</td>
</tr>
<tr>
<td>Pharmacogenomics in Oncology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group 5 Assessment</td>
<td></td>
<td>5.00</td>
</tr>
</tbody>
</table>

Copyright © 2020, American Society of Health-System Pharmacists and American College of Clinical Pharmacy, Inc. All rights reserved.
Learning Objectives
After participating in this CPE activity, learners should be able to:

Breast Cancer
ACPE #: 0204-9999-20-922-H01-P
- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with breast cancer.
- Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with breast cancer and her or his caregiver.
- Determine appropriate pharmacotherapy for a patient with breast cancer based on genomic test results.
- Identify appropriate diagnostic and prognostic tests related to breast cancer.
- Select relevant information and guidance for the public regarding breast cancer-related issues (e.g., cancer risk factors, prevention, screening).

Gynecologic Malignancies
ACPE #: 0204-9999-20-914-H01-P
- Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes of clinical trials and current treatment guidelines for a patient with a gynecologic malignancy.
- Discuss short- and long-term goals including post-therapy and survivorship, with a patient with a gynecologic malignancy and her caregiver.
- Compare and contrast the efficacy and toxicity of different routes of drug administration, including IP chemotherapy, in the treatment of ovarian cancer.
- Select relevant information and provide guidance for the public regarding gynecologic malignancy-related issues (e.g., risk factors, prevention and screening) for gynecologic malignancies.

Prostate Cancer
ACPE #: 0204-9999-20-916-H01-P
- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with prostate cancer.
- Identify appropriate diagnostic, prognostic, and monitoring tests for a patient with prostate cancer.
- Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with prostate cancer and his caregiver.
- Select relevant information and guidance for the public regarding prostate cancer-related issues (e.g., risk factors, prevention, screening).

Pediatric Malignancies and Supportive Care
ACPE #: 0204-9999-20-926-H01-P
- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for pediatric patients with cancer.
** Materials for this course will release 04/29/2020 **

- Assess the prognostic impact of relevant cancer-related molecular biology testing for a pediatric patient with cancer.
- Discuss with a pediatric patient who has cancer and his or her caregiver the short- and long-term treatment goals, including post-therapy and survivorship.
- Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer and supportive-care agents for a pediatric patient with cancer.
- Assess the regulatory, ethical, and patient rights issues related to conducting research, including informed consent and confidentiality.

**Upper Gastrointestinal and Hepatocellular Carcinomas**
ACPE #: 0204-9999-20-924-H01-P

- Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with esophageal, gastric, or hepatic malignancies.
- Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer agents used for gastrointestinal malignancies.
- Devise and communicate appropriate plans for preventing, monitoring, and treating radiation recall and other complications of radiation therapy.

**Bladder, Renal Cell, and Testicular Cancers**
ACPE #: 0204-9999-20-929-H01-P

- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with bladder, renal cell, or testicular carcinoma.
- Discuss short- and long-term goals, including post-therapy and survivorship, with a patient with bladder, renal cell, or testicular carcinoma and his or her caregiver.
- Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment with tyrosine kinase inhibitors and mTOR inhibitors.

**Melanoma and Non-Melanoma Skin Cancers**
ACPE #: 0204-9999-20-915-H01-P

- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with melanoma or non-melanoma skin cancer.
- Identify relevant cancer-related molecular biology testing for a patient with melanoma or non-melanoma skin cancer.
- Discuss short- and long-term goals, including post-therapy and survivorship, with a patient with melanoma or non-melanoma skin cancer and his or her caregiver.
- Select relevant information and guidance for the public regarding melanoma and non-melanoma skin cancer-related issues (e.g., risk factors, prevention, screening).
- Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment of melanoma and non-melanoma skin cancers, including thyroid level monitoring for chemotherapy agents, immune-mediated toxicities, and toxicity from BRAF inhibitors.
** Materials for this course will release 04/29/2020 **

Research Design, Statistics, and Evaluating Oncology Literature  
ACPE #: 0204-9999-20-912-H04-P  
- Evaluate the oncology literature, including study design, methodology, statistical analysis, and applicability of the results to clinical practice for oncology patient population.  
- Interpret the validity and results of various types of oncology studies (e.g., meta-analyses, noninferiority trials).  
- Identify potential sources of bias and evaluate the appropriateness of conclusions drawn based on outcomes in an oncology study report.  
- Select an appropriate statistical test (parametric or nonparametric) for use in evaluating findings from an oncology study based on the type of data (i.e., nominal, ordinal, continuous).  
- Interpret sensitivity, specificity, positive and negative predictive values, measures of effect, correlation, and regression for an oncology study.  
- Critique the validity and interpret the results of various types of oncology studies (e.g., meta-analyses, noninferiority trial).

Adult Acute Leukemias and Myelodysplastic Syndromes  
ACPE #: 0204-9999-20-928-H01-P  
- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adults with acute leukemia or myelodysplastic syndrome.  
- Assess the prognostic impact of relevant cancer-related molecular biology testing for an adult with acute leukemia or myelodysplastic syndrome.  
- Develop an appropriate plan for preventing, monitoring, and treating adverse reactions from pharmacotherapy for acute leukemia and myelodysplastic syndrome in an adult, including tumor lysis syndrome, neurotoxicity, differentiation syndrome, and cardiac toxicity from arsenic trioxide, and other agents as appropriate.  
- Determine appropriate pharmacotherapy for acute leukemia or myelodysplastic syndrome in an adult based on genomic test results.

Lymphomas  
ACPE #: 0204-9999-20-925-H01-P  
- Design an appropriate patient-specific treatment, supportive care, and monitoring plan to include effectiveness, toxicities and outcomes, based on the most current guidelines for patients with lymphoma.  
- Assess the prognostic impact of relevant cancer-related molecular biology testing.  
- Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lymphoma and other cancers, including chemotherapy-induced pulmonary toxicities and extravasation.
** Materials for this course will release 04/29/2020 **

**Chronic Leukemias**
ACPE #: 0204-9999-20-917-H01-P

- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with chronic leukemia.
- Assess the prognostic impact of relevant cancer-related molecular biology testing in a patient with chronic leukemia.
- Determine appropriate pharmacotherapy based on genomic test results in a patient with chronic leukemia.
- Develop an appropriate plan for preventing, monitoring, and treating infusion-related reactions from monoclonal antibodies used in the treatment of hematologic malignancies.
- Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for the treatment of cancers, including toxicities from tyrosine kinase inhibitors used to treat hematologic cancers.

**Hematopoietic Stem Cell Transplantation**
ACPE #: 0204-9999-20-921-H01-P

- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients undergoing hematopoietic stem cell transplantation (HSCT).
- Apply appropriate strategies to prevent toxicity from chemotherapy agents employed in HSCT conditioning regimens, and differentiate between myeloablative, non-myeloablative, and reduced-intensity HSCT conditioning regimens.
- Create a plan for prevention and management of acute and chronic graft-versus-host disease (GVHD) using appropriate systemic and ancillary therapies.
- Discuss short- and long-term treatment goals, including post-therapy and survivorship, with the patient undergoing HSCT and his or her caregiver.

**Lung Cancer**
ACPE #: 0204-9999-20-923-H01-P

- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lung cancer.
- Identify relevant cancer-related molecular biology testing for patients with lung cancer.
- Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer and supportive-care agents for a patient with lung cancer.
- Select relevant information and guidance for the public regarding lung cancer-related issues (e.g., risk factors, prevention, screening).
- Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lung cancer.
- Develop a prevention and management strategy for chemotherapy-induced nausea and vomiting for patients with any type of cancer.
Lower Gastrointestinal and Pancreatic Cancers
ACPE #: 0204-9999-20-927-H01-P

- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lower gastrointestinal (GI) or pancreatic cancers.
- Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with lower GI or pancreatic cancers and his or her caregiver.
- Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer and supportive-care agents for a patient with lower GI or pancreatic cancers.
- Select relevant information and guidance for the public regarding lower GI and pancreatic cancer-related issues (e.g., risk factors, prevention, screening).
- Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lower GI or pancreatic cancers, including chemotherapy-induced diarrhea, hand-foot syndrome, hand-foot skin reaction, neurotoxicity from oxaliplatin, and dermatologic toxicities from epidermal growth factor receptor inhibitors.

Head, Neck and Adult Central Nervous System (CNS) Malignancies
ACPE #: 0204-9999-20-930-H01-P

- Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with head, neck, adult central nervous system (CNS), or thyroid cancers.
- Select relevant information and guidance for the public regarding head and neck cancer-related issues (e.g., risk factors, prevention, screening).
- Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment of cancers including cancer cachexia, mucositis, and xerostomia.

Cancer-related Infectious Diseases
ACPE #: 0204-9999-20-931-H01-P

- Design an appropriate patient-specific management and monitoring plan to address potential infection-related problems that may arise during or following cancer treatment based on the current guidelines for treating cancer-related infectious diseases.
- Discuss short- and long-term treatment goals, including post-therapy, with a patient with a cancer-related infectious disease and his or her caregiver.

Oncology Practice Management
ACPE #: 0204-9999-20-920-H04-P

- Evaluate oncology pharmacy services for compliance with established regulations, professional practice standards, and procedures for handling and disposal of hazardous drugs.
- Select quality-improvement activities that enhance the safety and effectiveness of the medication-use processes in oncology patient care.
- Explain national accreditation and federal regulatory requirements for the care of cancer patients receiving chemotherapy or other hazardous drugs.
** Materials for this course will release 04/29/2020 **

- Explain medication reimbursement and patient assistance programs to optimize drug availability for oncology patients.
- Evaluate policies and procedures related to conducting research involving investigational drugs, including drug management in patients with cancer.

### Multiple Myeloma

ACPE #: 0204-9999-20-918-H01-P

- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients with multiple myeloma.
- Evaluate oncology pharmacy services for compliance with established REMS regulations and standards.
- Develop an appropriate plan for preventing, monitoring, and managing common problems associated with the treatment of cancers, including bone metastases in multiple myeloma patients and thromboembolism, hypercalcemia of malignancy, and spinal cord compression in all oncology patients.

### Adult Sarcoma

ACPE #: 0204-9999-20-919-H01-P

- Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adult patients with sarcoma.
- Adjust treatment and monitoring plans as needed based on tumor genetics and pharmacokinetics of anticancer and supportive-care agents (e.g., methotrexate).
- Develop an appropriate plan for preventing, monitoring, and managing common problems associated with the treatment of adult patients with cancer including neurotoxicity from ifosfamide and hemorrhagic cystitis.

### Pharmacogenomics in Oncology

ACPE #: 0204-9999-20-913-H01-P

- Identify appropriate considerations for genetic interpretation in both the germline and somatic settings utilizing a variety of next generation sequencing techniques.
- Apply the results from somatic genetic testing into therapeutic recommendations based on prognostic, predictive and patient characteristics.
- Recognize the place in therapeutic decision making for companion diagnostic testing.

### Faculty

Jessica Auten, Pharm.D., BCPS, BCOP
Clinical Pharmacy Specialist
UNC Medical Center
Chapel Hill, North Carolina
** Materials for this course will release 04/29/2020 **

Courtney C. Cavalieri, Pharm.D., BCOP*
Clinical Oncology Pharmacist
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah

Karen M. Fancher, Pharm.D., BCOP*
Assistant Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Clinical Pharmacy Specialist
Passavant Hospital - University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania

Christopher A. Fausel, Pharm.D., MHA, BCOP
Clinical Manager - Oncology Pharmacy
Indiana University Health
Chairman of the Board
Hoosier Cancer Research Network
Indianapolis, Indiana

Kelly Fritz, Pharm.D., BCOP
Oncology Clinical Coordinator
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah

Lauren Ice, Pharm.D., BCPS, BCOP
Clinical Pharmacy Specialist
Spectrum Health
Grand Rapids, Michigan

Steven Ludlow, Pharm.D., BCOP, BCPS
Medical Oncology Clinical Pharmacy Specialist
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida

Elyse A. MacDonald, Pharm.D., M.S., BCPS
Pharmacy Manager, Investigational Drug Service
University of Utah Health
Salt Lake City, Utah
** Materials for this course will release 04/29/2020 **

Janelle Mann, Pharm.D., BCOP  
Manager, Clinical Pharmacy Services  
Alvin J. Siteman Cancer Center  
Clinical Oncology Pharmacist  
Washington University School of Medicine  
St. Louis, Missouri

Tim Peterson, Pharm.D., BCOP  
Clinical Pharmacy Specialist  
Memorial Sloan Kettering Cancer Center  
New York, NY

Anthony J. Perissinotti, Pharm.D., BCOP  
Clinical Pharmacist Specialist - Inpatient Hematology  
Adjunct Clinical Assistant Professor  
University of Michigan Health System  
Ann Arbor, Michigan

Danielle Roman, Pharm.D., BCOP*  
Manager - Clinical Pharmacy Services  
Allegheny Health Network Cancer Institute  
Pittsburgh, Pennsylvania

Christine M. Walko, Pharm.D., FCCP, BCOP*  
Personalized Medicine Specialist  
H. Lee Moffitt Cancer Center  
DeBartolo Family Personalized Medicine Institute  
Associate Professor - Department of Oncologic Sciences  
USF Morsani College of Medicine  
Tampa, Florida

Jennifer Young, Pharm.D., BCOP  
Clinical Pharmacy Specialist – Pediatric Oncology  
Cincinnati Children’s Hospital Medical Center  
Cincinnati, OH

*Content Matter Experts

Reviewers
Angela T. Cassano, Pharm.D., BCPS, FASHP  
Susan R. Dombrowski, M.S., R.Ph.  
Courtney Alexander, Pharm.D., BCPS, BCOP  
Laura Bobolts, Pharm.D., BCOP  
Joseph Bubalo, Pharm.D., BCOP, BCPS
** Materials for this course will release 04/29/2020 **

Ryan Bycroft, Pharm.D., BCOP  
Nicholas Chow, Pharm.D., BCOP  
Jill Comeau, Pharm.D., BCOP  
Brette Conliffe, Pharm.D.  
Erik De Freitas, Pharm.D., MPH, MNSSS, BCOP  
Bryna Delman Ewachiw, Pharm.D., BCOP  
Amber Draper, Pharm.D., BCOP  
Hansen Ho, Pharm.D., BCOP  
Sarah Hoffman, Pharm.D., BCOP  
Christine Hong, Pharm.D., BCOP  
Shannon Hough, Pharm.D. BCOP  
Caren Hughes, Pharm.D., BCOP, MBA  
Mitchell Hughes, Pharm.D., BCPS, BCOP  
Anna Jan, Pharm.D., BCOP  
Ashley Johns, Pharm.D., M.S., BCOP, BCPS  
Jeff Kaiser, Pharm.D., BCOP, BCPS  
Minhee Kang, Pharm.D., BCOP, BCPS  
Lindsay Kaster, Pharm.D., BCOP  
Jennifer Kerns, Pharm.D., BCOP  
Michael Leung, Pharm.D., BCOP  
Suwicha Limvorasak, Pharm.D., BCOP  
Donald Moore, Pharm.D., BCPS, BCOP, DPLA  
Benjamin Moskoff, Pharm.D. BCOP  
Heather Pound, Pharm.D., BCPS, BCOP  
David Reeves, BCOP  
Melvin Rivera, Pharm.D., BCOP  
Glenn Roma, Pharm.D. PhD BCOP  
Katherine Saunders, Pharm.D., BCOP  
Gianni Scappaticci, Pharm.D., BCOP  
Danielle Schlafer, Pharm.D., BCOP  
Anne Spengler, Pharm.D., BCOP  
Jigar Trivedi, MS, Pharm.D., BCOP  
Cory Vela, Pharm.D., BCOP  
Kristin Wheatley, Pharm.D., BCOP  
Katie Won, Pharm.D., BCOP  
Rebecca Young, Pharm.D., BCOP  
Mark Zangardi, Pharm.D., BCOP  

Field Testers  
Courtney Alexander, Pharm.D., BCPS, BCOP  
Robert Appell, Pharm.D., BCOP  
Laura Bobolts, Pharm.D., BCOP  
Joseph Bubalo, Pharm.D., BCPS, BCOP  
Margaret Bush, BS Pharm, Ph.D., BCOP
Oncology Pharmacy Specialty Review Course for Recertification

** Materials for this course will release 04/29/2020 **

Ryan Bycroft, Pharm.D., BCOP
Christopher Campbell, Pharm.D., BCPS, BCOP
Eunah Cho, Pharm.D., BCOP
Nicholas Chow, Pharm.D., BCOP
Jill Comeau, Pharm.D., BCOP
Brette Conliffe, Pharm.D., BCOP
Erik De Freitas, Pharm.D., BCOP, MPH
Amber Draper, Pharm.D., BCOP
Linda Elnazir, Pharm.D., BCPS, BCOP
Bryna Ewachiw, Pharm.D., BCOP
Bradi Frei, Pharm.D., BCPS, BCOP
Alicia Gesenhues, Pharm.D., BCOP
Emily Graham, Pharm.D., MS, BCOP
Sean Green, Pharm.D., BCOP
Hansen Ho, Pharm.D., BCOP
Sarah Hoffman, Pharm.D., BCOP
Christine Hong, Pharm.D., BCOP
Shannon Hough, Pharm.D., BCOP
Caren Hughes, Pharm.D., BCOP
Mitchell Hughes, Pharm.D., BCPS, BCOP
Anna Jan, Pharm.D., BCOP
Austin Jenkins, Pharm.D., BCOP
Ashley Johns, Pharm.D., M.S., BCOP, BCPS
Angela Johnston Willis, Pharm.D., BCPS, BCOP
Jocelyn Joseph, Pharm.D., BCOP
Jeff Kaiser, Pharm.D., BCPS, BCOP
Minhee Kang, Pharm.D., BCOP, BCPS
Shraddha Kansagra, Pharm.D., BCOP
Lindsay Kaster, Pharm.D., BCOP
Jennifer Kerns, Pharm.D., BCOP
Carly Kesler, Pharm.D., BCOP
Michael Leung, Pharm.D., BCOP
Whitney Lewis, Pharm.D., BCOP
Suwicha Limvorasak, Pharm.D., BCOP
Valerie Lindeborg, Pharm.D., BCOP, BCSCP
Robin Lockhorst, Pharm.D.
Samantha Luk, Pharm.D., BCOP
Robert Luschen, Pharm.D., BCOP
Margaret McGuinness, Pharm.D., BCOP
Donald Moore, Pharm.D., BCPS, BCOP, DPLA
Kesha Morgan, Pharm.D., BCPS, BCOP
Benjamin Moskoff, Pharm.D. BCOP
David Nowinski, Pharm.D., BCOP
Chukwuemeka Nzelibe, Pharm.D., BCOP, MBA

Copyright © 2020, American Society of Health-System Pharmacists and American College of Clinical Pharmacy, Inc.
All rights reserved.
** Materials for this course will release 04/29/2020 **

Nabil Omar, Pharm.D., BCOP
Kara Osborne, Pharm.D., BCOP
Carol Peek, Pharm.D., BCOP
Laura Poggi, Pharm.D., BCOP
Heather Pound, Pharm.D., BCPS, BCOP
Heena Rathod, Pharm.D., BCOP
Mohammad Rattu, Pharm.D., BCOP, BCPS, BCGP
David Reeves, Pharm.D., BCOP
Amy Riedel, Pharm.D., BCPS, BCOP
Melvin Rivera, Pharm.D., BCOP
Glenn Roma, Pharm.D., Ph.D., BCOP
Kristen Rychalsky, Pharm.D., BCPS, BCOP
Stephanie Sanders, Pharm.D., BCOP
Katherine Saunders, Pharm.D., BCOP
Gianni Scappaticci, Pharm.D., BCOP
Hope Schenk, Pharm.D., BCOP
Danielle Schlafer, Pharm.D., BCOP
Brian Seiki, Pharm.D., BCOP
Meenakshi Shelat, Pharm.D., BCOP
Sunao Slayton, Pharm.D., BCOP
Cynthia Spencer, BS Pharm, BCOP
Anne Spengler, Pharm.D., BCOP
Matthew St.Amand, Pharm.D., BCOP
Lindsay Stansfield, Pharm.D., BCPS, BCOP
Chipman Stroud, Pharm.D., BCOP
Minal Surati, Pharm.D., BCOP
Chia Jie Tan, BPharm(Hons), BCOP
Christian Thomas, Pharm.D., BCOP
Ajoke Tijani, Pharm.D., BCOP
Jigar Trivedi, MS, Pharm.D., BCOP
Jessica Unzaga, Pharm.D., BCPS, BCOP
Cory Vela, Pharm.D., BCOP
Alma Villescas, R.Ph., BCOP
Sheng Fan Wang, Ph.D., BCOP
Kristin Wheatley, Pharm.D., BCOP
Eryn Whitaker, Pharm.D., BCOP, APh
Katie Won, Pharm.D., BCOP
Vincent WONG, MPharm, BCGP, BCPS, BCOP
Chen Xu, Ph.D., BCOP
Lily Yan, Pharm.D., BCOP
Rebecca Young, Pharm.D., BCOP
Mark Zangardi, Pharm.D., BCOP

Copyright © 2020, American Society of Health-System Pharmacists and American College of Clinical Pharmacy, Inc.
All rights reserved.
Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP and ACCP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual or his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ASHP and ACCP education activities are qualified and selected by ASHP and ACCP and required to disclose any relevant financial relationships with commercial interests. ASHP and ACCP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

Karen M. Fancher, Pharm.D., BCOP: Consultant, AstraZeneca, LP
Anthony J. Perissinotti, Pharm.D., BCOP: Consultant, Servier
Christine M. Walko, Pharm.D., BCOP, FCCP: Consultant, Foundation Medicine; MTB Consultant, Jackson Genetic Laboratories; MTB Consultant, Intermountain Healthcare

All other planners, presenters, reviewers, ASHP and ACCP staff and others with an opportunity to control content report no financial relationships relevant to this activity.

Methods and CE Requirements
Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity.
Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

System Technical Requirements
Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites.

View the minimum technical and system requirements for learning activities.

Development
These activities were developed by ASHP and ACCP.